Patent · US Active

Humanized anti-human CD19 antibodies and methods of use

US11286300B2 · kind B2 · utility

8Cited by

59References

8Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Claudia Ferrara Koller · Schlieren, CH
Guy Georges · Habach, DE
Alexander Haas · Munich, DE
Hubert Kettenberger · Munich, DE
Ekkehard Moessner · Kreuzlingen, CH
Tilman Schlothauer
Michael Molhoj · Munich, DE
Laurent Lariviere · Ostendorf, DE

Key dates

Filing date	Sep 30, 2016
Grant date	Mar 29, 2022
Priority date	—
Expiry date	Sep 30, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Herein is reported an antibody that specifically binds to human CD 19, wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 03, (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 11, (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 05, (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or 28, (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 07, and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 08, as well as methods of using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.